Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Osteosarcoma Recurrent: early-phase trial registry
2 of 5 indexed Osteosarcoma Recurrent trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Osteosarcoma Recurrent: 5 US clinical trials tracked, 2 recruiting.
Osteosarcoma Recurrent is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Sarcoma Alliance for Research through Collaboration, running 1 of these trials.
Enrollment posture brief
Registry condition osteosarcoma-recurrent
OPEN 2 | RECR 40% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Osteosarcoma Recurrent lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Osteosarcoma Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Osteosarcoma Recurrent is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Osteosarcoma Recurrent research.
Sarcoma Alliance for Research through Collaboration accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Osteosarcoma Recurrent trials plan to enrol fewer than 100 people.
Median target enrolment is 24 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Osteosarcoma Recurrent research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Emory University
NCT07144254
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Montefiore Medical Center
NCT06892678
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Dana-Farber Cancer Institute
NCT04417062
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
NCT04803877
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03628209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Osteosarcoma Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Osteosarcoma Recurrent trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Osteosarcoma Recurrent page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Osteosarcoma Recurrent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sarcoma Alliance for Research through Collaboration sponsors the most Osteosarcoma Recurrent trials on record, review their full trial history before evaluating a specific study. See Sarcoma Alliance for Research through Collaboration's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Osteosarcoma Recurrent condition card totals 5 registered trials; most-linked intervention Nivolumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.